Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.

Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.

BACKGROUND: Cotrimoxazole prophylaxis reduces morbidity and mortality in HIV-1-infected children, but mechanisms for these benefits are unclear. METHODS: CHAP was a randomized trial comparing cotrimoxazole prophylaxis with placebo in HIV-infected children in Zambia where background bacterial resista...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Mulenga, V, Ford, D, Walker, A, Mwenya, D, Mwansa, J, Sinyinza, F, Lishimpi, K, Nunn, A, Gillespie, S, Zumla, A, Chintu, C, Gibb, D
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2007

Míreanna comhchosúla

The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children.
de réir: Walker, A, et al.
Foilsithe / Cruthaithe: (2007)

Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia.
de réir: Mwenya, D, et al.
Foilsithe / Cruthaithe: (2010)

Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial.
de réir: Walker, A, et al.
Foilsithe / Cruthaithe: (2006)

Adherence to both cotrimoxazole and placebo is associated with improved survival among HIV-infected Zambian children.
de réir: Walker, A, et al.
Foilsithe / Cruthaithe: (2009)

Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis.
de réir: Prendergast, A, et al.
Foilsithe / Cruthaithe: (2011)

Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.
de réir: Chintu, C, et al.
Foilsithe / Cruthaithe: (2004)

The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.
de réir: Ryan, M, et al.
Foilsithe / Cruthaithe: (2008)

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
de réir: Prendergast, A, et al.
Foilsithe / Cruthaithe: (2016)

Cotrimoxazole-Induced Hypoglycemia in an HIV-Infected Patient
de réir: Christine A Hughes, et al.
Foilsithe / Cruthaithe: (2001-01-01)

Co-trimoxazole prophylaxis in African children with HIV-1 - Reply
de réir: Gibb, D, et al.
Foilsithe / Cruthaithe: (2005)

Cotrimoxazole prophylaxis for infants exposed to HIV infection
de réir: Stephen M. Graham

Cotrimoxazole prophylaxis for infants exposed to HIV infection
de réir: Stephen M. Graham
Foilsithe / Cruthaithe: (2004-04-01)

Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation
de réir: Bourke, CD, et al.
Foilsithe / Cruthaithe: (2019)

Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.
de réir: Christopher J Hoffmann, et al.
Foilsithe / Cruthaithe: (2014-01-01)

Linking HIV-infected TB patients to cotrimoxazole prophylaxis and antiretroviral treatment in India.
de réir: Neeraj Raizada, et al.
Foilsithe / Cruthaithe: (2009-06-01)

Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection
de réir: Gill Christopher J., et al.
Foilsithe / Cruthaithe: (2004-01-01)

Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
de réir: Fillekes, Q, et al.
Foilsithe / Cruthaithe: (2013)

Identification of Pneumocystis carinii DNA by polymerase chain reaction in necropsy lung samples from children dying of respiratory tract illnesses.
de réir: Kasolo, F, et al.
Foilsithe / Cruthaithe: (2002)

Identification of Pneumocystis carinii DNA in oropharyngeal mouth washes from AIDS children dying of respiratory illnesses.
de réir: Lishimpi, K, et al.
Foilsithe / Cruthaithe: (2002)

Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
de réir: Oudijk, J, et al.
Foilsithe / Cruthaithe: (2012)

Estimating the impact of alternative programmatic cotrimoxazole strategies on mortality among children born to mothers with HIV: A modelling study.
de réir: Shrey Mathur, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects
de réir: Haberer, J, et al.
Foilsithe / Cruthaithe: (2011)

Operational research in malawi: making a difference with cotrimoxazole preventive therapy in patients with tuberculosis and HIV
de réir: Schouten Erik J, et al.
Foilsithe / Cruthaithe: (2011-07-01)

Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants.
de réir: Scott Dryden-Peterson, et al.
Foilsithe / Cruthaithe: (2013-01-01)

Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries?
de réir: Anna Coutsoudis, et al.

Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries?
de réir: Anna Coutsoudis, et al.
Foilsithe / Cruthaithe: (2010-12-01)

Factors associated with coverage of cotrimoxazole prophylaxis in HIV-exposed children in South Africa.
de réir: Dhayendre Moodley, et al.
Foilsithe / Cruthaithe: (2013-01-01)

Identification of the phenotypic, genotypic and fitness correlates of non-B subtype HIV-1 NRTI resistance through longitudinal analysis of children with virological failure in the developing world
de réir: Mbisa, J, et al.
Foilsithe / Cruthaithe: (2010)

Dynamics of emergence and linkage of HIV reverse transcriptase Q151M MDR complex in children within first-line antiretroviral rollout uncovered by single-genome sequencing
de réir: Mbisa, J, et al.
Foilsithe / Cruthaithe: (2009)

Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.
de réir: Fillekes, Q, et al.
Foilsithe / Cruthaithe: (2012)

Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis.
de réir: Cheng, A, et al.
Foilsithe / Cruthaithe: (2009)

Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
de réir: Burger, D, et al.
Foilsithe / Cruthaithe: (2010)

A mortality review of tuberculosis and HIV co-infected patients in Mahalapye, Botswana: Does cotrimoxazole preventive therapy and/or antiretroviral therapy protect against death?
de réir: Stephane Tshitenge, et al.
Foilsithe / Cruthaithe: (2018-11-01)

Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
de réir: Gupta, R, et al.
Foilsithe / Cruthaithe: (2010)

Successful Treatment of Actinomycetoma with Combination of Cotrimoxazole and Tetracycline
de réir: Verdy Verdy, et al.
Foilsithe / Cruthaithe: (2016-03-01)

Necrólisis tóxica epidérmica inducida por cotrimoxazol
de réir: Rolando Rodríguez Hernández, et al.

Comparison between itraconazole and cotrimoxazole in the treatment of paracoccidiodomycosis.
de réir: Ricardo de Souza Cavalcante, et al.
Foilsithe / Cruthaithe: (2014-04-01)

Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial.
de réir: Zacchaeus Anywaine, et al.
Foilsithe / Cruthaithe: (2018-01-01)

Impact of Anti-Retroviral Treatment and Cotrimoxazole Prophylaxis on Helminth Infections in HIV-Infected Patients in Lambaréné, Gabon.
de réir: Saskia Janssen, et al.
Foilsithe / Cruthaithe: (2015-05-01)

National policy development for cotrimoxazole prophylaxis in Malawi, Uganda and Zambia: the relationship between Context, Evidence and Links
de réir: Chishinga Nathaniel, et al.
Foilsithe / Cruthaithe: (2011-06-01)